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The aim of the study was to compare the diagnostic performance of endoscopic ultrasonography (EUS), computed tomography
(CT), and
18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in staging of oesophageal cancer. PubMed was
searched to identify English-language articles published before January 2006 and reporting on diagnostic performance of EUS, CT,
and/or FDG-PET in oesophageal cancer patients. Articles were included if absolute numbers of true-positive, false-negative, false-
positive, and true-negative test results were available or derivable for regional, celiac, and abdominal lymph node metastases and/or
distant metastases. Sensitivities and specificities were pooled using a random effects model. Summary receiver operating characteristic
analysis was performed to study potential effects of study and patient characteristics. Random effects pooled sensitivities of EUS, CT,
and FDG-PET for regional lymph node metastases were 0.80 (95% confidence interval 0.75–0.84), 0.50 (0.41–0.60), and 0.57
(0.43–0.70), respectively, and specificities were 0.70 (0.65–0.75), 0.83 (0.77–0.89), and 0.85 (0.76–0.95), respectively. Diagnostic
performance did not differ significantly across these tests. For detection of celiac lymph node metastases by EUS, sensitivity and
specificity were 0.85 (0.72–0.99) and 0.96 (0.92–1.00), respectively. For abdominal lymph node metastases by CT, these values were
0.42 (0.29–0.54) and 0.93 (0.86–1.00), respectively. For distant metastases, sensitivity and specificity were 0.71 (0.62–0.79) and 0.93
(0.89–0.97) for FDG-PET and 0.52 (0.33–0.71) and 0.91 (0.86–0.96) for CT, respectively. Diagnostic performance of FDG-PET for
distant metastases was significantly higher than that of CT, which was not significantly affected by study and patient characteristics. The
results suggest that EUS, CT, and FDG-PET each play a distinctive role in the detection of metastases in oesophageal cancer patients.
For the detection of regional lymph node metastases, EUS is most sensitive, whereas CT and FDG-PET are more specific tests. For
the evaluation of distant metastases, FDG-PET has probably a higher sensitivity than CT. Its combined use could however be of
clinical value, with FDG-PET detecting possible metastases and CT confirming or excluding their presence and precisely determining
the location(s).
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To optimise the selection of patients with oesophageal cancer for a
curative or palliative treatment option, it is important to determine
the depth of infiltration of the tumour into the oesophageal wall
(T stage), and the presence of malignant regional lymph nodes
(N stage) and distant metastases (M stage). For N stage, N0 and N1
indicate the absence or presence of regional lymph node
metastases, respectively. Similarly, M0 indicates the absence and
M1 the presence of distant metastases (Fleming et al, 1997).
Whether a malignant lymph node is defined as N1 or M1 depends
on the location of the primary tumour. For example, malignant
celiac lymph nodes are staged as M1a if the primary tumour is
located in the distal part of the oesophagus, but as stage M1b if the
tumour is located in the more proximal part of the oesophagus and
as N1 if the tumour is located in the gastric cardia (Thompson,
1997). Distant metastases from oesophageal cancer are most
frequently detected in celiac and supraclavicular lymph nodes,
liver, lung, and adrenal glands (Quint et al, 1995).
Endoscopic ultrasonography (EUS) is often used to determine
the depth of tumour invasion and the presence of malignant
regional and celiac lymph nodes in patients with oesophageal
cancer. Both computed tomography (CT) and
18F-fluoro-2-deoxy-
D-glucose positron emission tomography (FDG-PET) are com-
monly applied to determine whether malignant lymph nodes or
distant metastases are present.
It is known that EUS, CT, and FDG-PET each have certain
limitations. For example, only lymph nodes in the proximity of the
oesophageal and gastric wall can be visualised with EUS, as it has a
limited penetration depth of approximately 5cm. As a conse-
quence, metastases in distant lymph nodes or organs can often not
be detected by EUS (Kienle et al, 2002). Computed tomography is
not able to detect metastases in normal-sized lymph nodes.
Furthermore, an enlarged lymph node may contain metastases, but
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scan also be enlarged as a consequence of inflammation (Halvorsen
and Thompson, 1984; Finch et al, 1997; Choi et al, 2000). The same
is true for abnormal findings in the liver or adrenal glands, for
which it is not always clear whether these are metastases or not.
Detection of metastases by FDG-PET is based on an altered tissue
glucose metabolism. Biochemical changes are known to appear
earlier in time than structural changes and also they are more
specific (Block et al, 1997; Flanagan et al, 1997). Nevertheless,
lesions less than 1 cm in diameter can be missed by FDG-PET
(Lerut et al, 2000).
In this study, we evaluated the diagnostic performance of EUS,
CT, and FDG-PET as has been reported in the literature. In
addition, we determined whether only one or a combination of
these investigations should be used in the staging of oesophageal
cancer. The focus in this meta-analysis was on the application of
EUS for the detection of malignant regional and celiac lymph
nodes, the use of CT for the detection of malignant regional and
abdominal lymph nodes and distant metastases, and the use of
FDG-PET for the detection of malignant regional lymph nodes and
distant metastases.
MATERIALS AND METHODS
Literature search and data extraction
A PubMed literature search was performed identifying all articles
related to the diagnostic use of EUS, CT, and FDG-PET in patients
with oesophageal cancer. Search terms that were used to identify
such articles were combinations of ‘esophagus’, ‘oesophagus’,
‘cancer’, ‘neoplasm’, ‘carcinoma’, ‘endoscopic ultrasonography’,
‘endosonography’ ‘EUS’, ‘computed tomography’, ‘CT’, ‘positron
emission tomography’, and ‘PET’. Abstracts obtained from these
searches were evaluated. Articles containing information on the
results of EUS, CT, and/or FDG-PET for N and/or M stage of
oesophageal cancer and published in the English literature before
January 2006 were reviewed. Articles were included if the absolute
numbers of true-positive (TP), false-negative (FN), false-positive
(FP), and true-negative (TN) test results were available or
derivable from the article, which allowed us to construct 2 2
contingency tables. The references of articles and reviews, found in
the literature search, were also examined to find additional articles
that met the inclusion criteria. Studies with potentially overlapping
study populations were excluded. For this, we included only the
study with the largest patient population and published latest in
time, whereas the previous study, with often a smaller subgroup of
patients, was excluded. Also excluded were articles published in
abstract form only, case reports, editorials, and reviews.
In addition, articles containing the results of patients who had
undergone prior radiation and/or chemotherapy were excluded if
the result of the reference standard could have been influenced by
the administration of this treatment. The reference standard was
resection, result of fine-needle aspiration (FNA), follow-up with
radiographic techniques, and/or clinical follow-up in the article.
Two independent readers (EV, PS) extracted the data from the
included articles. The absolute numbers of TP, FN, FP, and TN test
results were retrieved or calculated from the published data. Other
characteristics that were extracted from each study were origin and
publication year of an article, mean age of patients, proportion of
males (as percentage of total number of patients), tumour
histology, retrospective or prospective set-up of the study, whether
or not the patients were consecutively included, whether or not the
test results were blindly interpreted, and the reference standard
that was used in the study. For articles containing EUS results, the
type of EUS probe, whether or not FNA was performed for
suspicious lymph nodes, and whether or not dilation was
performed in patients with a stenotic tumour were also recorded.
From articles containing CT results, information on the type of CT
scanner and use of a contrast agent was obtained. From articles
containing FDG-PET results, the type of PET scanner was
recorded. Inconsistent findings between the two readers were
discussed and agreed upon by consensus.
Statistical analysis
To determine whether publication bias, that is, the selective
reporting of manuscripts with more positive results, was present,
funnel plots were constructed. A funnel plot is an epidemiologic
method for assessing the presence of publication bias. For this, the
measure of study size is plotted against the measure of interest. In
this study, the measure of study size was the number of patients
included in the study, whereas the measure of interest was the
natural logarithm of the diagnostic odds ratio (D). The idea is that
studies with the largest study size will estimate D most accurately,
whereas studies with a smaller study size will have a more variable
result, with both lower and higher values of D compared to the
larger studies. If this is the case, the plot will have a symmetric,
inverted funnel shape. If publication bias is present, the left base of
the plot will disappear and the plot is asymmetric and skewed
(Terrin et al, 2005). Symmetry and shape of the funnel plots were
determined by means of visual inspection. To allow assessment of
the presence of publication bias by visual inspection, the number
of included articles had to be more than 10.
Sensitivities and specificities of EUS, CT, and FDG-PET were
pooled using a random effects model. With this method, the
variability between studies is taken into account. To estimate the
relationship between sensitivities and specificities of each inves-
tigation, a random effects summary receiver operating character-
istic (SROC) analysis was performed. In an SROC analysis, the
logits (log odds) of sensitivity and 1 specificity are subtracted to
calculate D (D¼ln(sensitivity/(1 sensitivity)) ln((1 specificity)/
specificity)). D is the log of the diagnostic odds ratio, which
represents a summary measure of the diagnostic performance or
discriminatory power of an investigation. D ranges from zero to
infinity. A value close to zero or far from 1 represents an
investigation with good diagnostic performance. The logits
are summed to calculate S (S¼ln(sensitivity/(1 sensitivity))þ
ln((1 specificity)/specificity)), which is a proxy for the positivity
criterion of the diagnostic test. When institutions use different
thresholds for scoring a test result as positive, different positivity
criteria will exist among studies. Subsequently, a linear regression
model D¼aþbS was estimated, weighted by the inverse of the
variance of D. We have chosen to perform a weighted regression,
as the unweighted regression may not highlight larger studies.
Additional covariates (such as publication year, number of
patients, mean age, proportion of males, whether or not the study
was performed prospectively, whether or not the patients were
included consecutively, and whether or not the test results were
interpreted in a blinded fashion) were added to the model to adjust
for differences in study and patient characteristics. The effect of a
covariate was expressed in the relative diagnostic odds ratio (a
value 41, 1, or o1 means superior, equal, or inferior diagnostic
performance, respectively) and was considered statistically sig-
nificant if Po0.05. The meta and metareg commands of STATA 8.0
were used to perform the meta-analysis.
RESULTS
Literature search and data extraction
The PubMed literature search for the identification of articles
relating to the diagnostic use of EUS in oesophageal cancer
patients resulted in 573 hits on the search terms. In total, 31
articles on EUS for regional lymph node metastases (Tio et al,
1990; Botet et al, 1991; Rice et al, 1991; Ziegler et al, 1991; Dittler
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sand Siewert, 1993; Grimm et al, 1993; Greenberg et al, 1994;
Yoshikane et al, 1994; Binmoeller et al, 1995; Hasegawa et al, 1996;
Hunerbein et al, 1996; Natsugoe et al, 1996; Pham et al, 1998;
Vickers, 1998; Bowrey et al, 1999; Catalano et al, 1999; Nishimaki
et al, 1999; Salminen et al, 1999; Choi et al, 2000; Nesje et al, 2000;
Richards et al, 2000; Shinkai et al, 2000; Vazquez-Sequeiros et al,
2001, 2003; Rasanen et al, 2003; Wu et al, 2003; Heeren et al, 2004;
Sihvo et al, 2004; DeWitt et al, 2005; Lowe et al, 2005; Pedrazzani
et al, 2005) and five articles on EUS for celiac lymph node
metastases were included (Binmoeller et al, 1995; Catalano et al,
1999; Eloubeidi et al, 2001; Vazquez-Sequeiros et al, 2001; Parmar
et al, 2002) (Table 1). For CT, the literature search gave 1091 hits.
Seventeen articles on CT for regional lymph node metastases met
the inclusion criteria (Quint et al, 1985; Botet et al, 1991; Ziegler
et al, 1991; Sondenaa et al, 1992; Greenberg et al, 1994; Yoshikane
et al, 1994; Flanagan et al, 1997; Nishimaki et al, 1999; Choi et al,
2000; Wren et al, 2002; Rasanen et al, 2003; Vazquez-Sequeiros
et al, 2003; Wu et al, 2003; Yoon et al, 2003; Heeren et al, 2004;
Sihvo et al, 2004; Lowe et al, 2005). As some articles containing the
results of CT not only reported on celiac lymph node metastases,
but also on other abdominal lymph node metastases, we decided to
include all articles (five in total) with these results (Quint et al,
1985; Becker et al, 1986; Watt et al, 1989; Van Overhagen et al,
1993; Parmar et al, 2002). In addition, seven articles on CT for
distant metastases were included (Van Overhagen et al, 1993;
Flamen et al, 2000; Wren et al, 2002; Rasanen et al, 2003; Yoon
et al, 2003; Sihvo et al, 2004; Lowe et al, 2005) (Table 2). Our
literature search for FDG-PET gave 163 hits. We included 10
articles on FDG-PET for regional lymph node metastases
(Flanagan et al, 1997; Luketich et al, 1997; Choi et al, 2000; Lerut
et al, 2000; Wren et al, 2002; Rasanen et al, 2003; Yoon et al, 2003;
Heeren et al, 2004; Sihvo et al, 2004; Lowe et al, 2005). Nine articles
were included on FDG-PET for distant metastases (Luketich et al,
1997; Flamen et al, 2000; Lerut et al, 2000; Wren et al, 2002;
Rasanen et al, 2003; Yoon et al, 2003; Heeren et al, 2004; Sihvo
et al, 2004; Lowe et al, 2005) (Table 3). We found that the
interobserver agreement for the data extraction was excellent
(k40.80).
Regional lymph node metastases
Random effects pooled sensitivity and specificity of EUS for N
stage were 0.80 (95% confidence interval (CI) 0.75–0.84) and 0.70
(95% CI 0.65–0.75), respectively, and the pooled log odds ratio
was 1.94 (95% CI 1.71–2.17) (Table 4). Visual inspection of the
funnel plot revealed that the plot was symmetric (Figure 1), which
implies that the presence of publication bias was unlikely. In the
present study, no statistically significant differences were found
between EUS and EUS-FNA for N stage.
Random effects pooled sensitivity and specificity of CT for
regional lymph node metastases were 0.50 (95% CI 0.41–0.60) and
0.83 (95% CI 0.77–0.89), respectively. The pooled log odds ratio
was 1.40 (95% CI 1.08–1.72) (Table 4). No evidence for publication
bias was found (Figure 2).
Random effects pooled sensitivity and specificity of FDG-PET
for regional lymph node metastases were 0.57 (95% CI 0.43–0.70)
and 0.85 (95% CI 0.76–0.95), respectively. The pooled log odds
ratio was 1.71 (95% CI 1.22–2.20) (Table 4). It was not possible to
assess whether publication bias was present, as the number of
articles was too small (n¼10).
The estimated SROC curves are shown in Figure 3. The
differences between the curves of EUS, CT, and FDG-PET for N
staging were not statistically significant. The relative diagnostic
odds ratio of CT vs EUS was 0.76 (95% CI 0.48–1.21; P¼0.25) and
of FDG-PET vs EUS 0.95 (95% CI 0.54–1.67; P¼0.86). Thus,
taking into account the inverse relationship between sensitivity
and specificity and different test thresholds across different
studies, there were no significant differences in diagnostic
performance across these tests for the detection of regional lymph
node metastases. Study and patient characteristics also did not
show any significant effect on the diagnostic performance of the
tests. Nevertheless, comparing the pooled sensitivities and pooled
specificities across the tests, statistically significant differences
were present, that is, the 95% CI did not always overlap.
Sensitivities of CT and FDG-PET for N stage were significantly
lower than that of EUS, whereas specificities were significantly
higher. This implies that these investigations work at different
points on the SROC curve, that is, with EUS being more sensitive
and less specific than CT and FDG-PET for regional lymph node
metastases, but overall having a similar diagnostic performance
(Table 4).
Celiac and abdominal lymph node metastases
Random effects pooled sensitivity and specificity of EUS for celiac
lymph node metastases were 0.85 (95% CI 0.72–0.99) and 0.96
(95% CI 0.92–1.00), respectively, and the pooled log odds ratio
was 3.89 (95% CI 2.67–5.11) (Table 4). As the number of articles
was only five, assessment of publication bias was not possible.
Random effects pooled sensitivity and specificity of CT for
malignant abdominal lymph nodes were 0.42 (95% CI 0.29–0.54)
and 0.93 (95% CI 0.86–1.00), respectively. The pooled log odds
ratio measured 1.74 (95% CI 0.45–3.04) (Table 4). It was not
possible to assess whether publication bias was present.
We have not included an SROC curve for EUS (celiac lymph
node metastases) and CT (abdominal lymph node metastases) as
we think that these curves could not be fairly compared with each
other.
Distant metastases
Random effects pooled sensitivity and specificity of CT for distant
metastases were 0.52 (95% CI 0.33–0.71) and 0.91 (95% CI 0.86–
0.96), respectively. The pooled log odds ratio was 2.10 (95% CI
1.59–2.62) (Table 4). The number of articles was too low to assess
publication bias.
Random effects pooled sensitivity and specificity of FDG-PET
for the detection of distant metastases were 0.71 (95% CI 0.62–
0.79) and 0.93 (95% CI 0.89–0.97), respectively. The pooled log
odds ratio was 2.93 (95% CI 2.41–3.45) (Table 4). Assessment of
publication bias was not possible.
If the pooled sensitivities, specificities, and log odds ratios
across tests were compared separately, we found higher values of
FDG-PET for the detection of distant metastases compared to CT,
although not statistically significant. Nevertheless, the SROC
analysis showed that the diagnostic performance of FDG-PET
was significantly higher than the diagnostic performance of CT
(relative diagnostic odds ratio¼2.26 (95% CI 1.09–4.71), Po0.03),
taking into account the inverse relationship between sensitivity
and specificity and different test thresholds across the studies
(Figure 4).
To adjust for differences in study characteristics, various
covariates were added in the SROC analysis. This showed that
the covariates were not statistically significant (P40.05), and there
was significant difference between the diagnostic performance of
CT and FDG-PET for the detection of distant metastases.
DISCUSSION
We performed a meta-analysis to determine the value of EUS, CT,
and FDG-PET in the staging of oesophageal cancer patients. We
found that EUS was significantly more sensitive but less specific
than CT and FDG-PET for the detection of regional lymph node
metastases. The overall diagnostic performance of the three tests,
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sTable 1 Characteristics of studies containing absolute numbers of TP, FN, FP, and TN test results of EUS for regional and celiac lymph node metastases
Study Study type
Blinded
interpretation
of test results
Resection as
reference
standard
FNA as
reference
standard
Other reference
standard
Number of
patients Sensitivity (%) Specificity (%)
Regional lymph node metastases
Tio et al (1990) Not reported Not reported Yes No 111 73/77 (95) 17/34 (50)
Ziegler et al (1991) Prospective Not reported Yes No Autopsy 37 16/25 (64) 9/12 (75)
Rice et al (1991) Not reported Not reported Yes No 20 7/10 (70) 7/10 (70)
Botet et al (1991) Prospective Not reported Yes No 50 35/36 (97) 9/14 (64)
Grimm et al (1993) Prospective Not reported Yes No 63 37/41 (90) 17/22 (77)
Dittler and Siewert (1993) Not reported Not reported Yes No 167 85/114 (75) 37/53 (70)
Yoshikane et al (1994) Not reported Yes Yes No 25 7/12 (58) 11/13 (85)
Greenberg et al (1994) Prospective Not reported Yes No 16 6/10 (60) 6/6 (100)
Binmoeller et al (1995) Prospective Not reported Yes No 38 26/29 (90) 4/9 (44)
Hasegawa et al (1996) Not reported Not reported Yes No 18 4/8 (50) 8/10 (80)
Natsugoe et al (1996) Prospective Not reported Yes No 37 4/5 (80) 28/32 (88)
Hunerbein et al (1996) Prospective Not reported Yes No 17 13/14 (93) 2/3 (67)
Pham et al (1998) Prospective Yes Yes No 28 14/16 (88) 7/12 (58)
Vickers, 1998 Prospective Not reported Yes No 49 35/36 (97) 7/13 (54)
Bowrey et al (1999) Not reported Not reported Yes No 30 17/19 (89) 7/11 (64)
Salminen et al (1999) Prospective Yes Yes No 32 19/20 (95) 4/12 (33)
Catalano et al (1999) Prospective Not reported Yes Yes 149 75/95 (79) 34/54 (63)
Nishimaki et al (1999) Prospective Not reported Yes No 166 88/110 (80) 33/56 (59)
Shinkai et al (2000) Not reported Not reported Yes No 102 41/54 (76) 28/48 (58)
Nesje et al (2000) Prospective Not reported Yes No 54 36/46 (78) 6/8 (75)
Richards et al (2000) Retrospective Not reported Yes No 69 19/42 (45) 18/27 (67)
Choi et al (2000) Prospective Yes Yes No 45 15/30 (50) 11/15 (73)
Vazquez-Sequeiros et al (2001) Retrospective Not reported Yes No 33 14/22 (64) 9/11 (82)
Vazquez-Sequeiros et al (2003) Prospective Yes Yes Yes 124 68/85 (80) 32/39 (82)
Wu et al (2003) Not reported No Yes No 31 13/19 (68) 9/12 (75)
Rasanen et al (2003) Prospective Not reported Yes No Follow-up 32 17/19 (89) 7/13 (54)
Heeren et al (2004) Not reported Yes Yes Yes Follow-up 43 18/26 (69) 13/17 (76)
Sihvo et al (2004) Prospective No Yes No 43 22/26 (85) 9/17 (53)
Lowe et al (2005) Prospective Yes Yes Yes 59 38/44 (86) 10/15 (67)
Pedrazzani et al (2005) Retrospective Not reported Yes No 51 25/37 (68) 10/14 (71)
DeWitt et al (2005) Retrospective Not reported Yes No 102 48/66 (73) 28/36 (78)
Celiac lymph node metastases
Binmoeller et al (1995) Prospective Not reported Yes No 35 3/4 (75) 29/31 (94)
Catalano et al (1999) Prospective Not reported Yes Yes 149 19/23 (83) 124/126 (98)
Eloubeidi et al (2001) Retrospective No Yes Yes 102 48/62 (77) 34/40 (85)
Vazquez-Sequeiros et al (2001) Retrospective Not reported Yes No 33 3/4 (75) 29/29 (100)
Parmar et al (2002) Retrospective Not reported Yes Yes 20 18/18 (100) 1/2 (50)
TP¼true-positive; FN¼false-negative; FP¼false-positive; TN¼true-negative; EUS¼endoscopic ultrasonography; FNA¼fine-needle aspiration.
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sTable 2 Characteristics of studies containing absolute numbers of TP, FN, FP, and TN test results of CT for regional lymph node metastases, abdominal lymph node metastases, and distant metastases
Study Study type
Blinded
interpretation
of test results
Resection as
reference
standard
FNA as
reference
standard
Other reference
standard
Number of
patients Sensitivity (%) Specificity (%)
Regional lymph node metastases
Quint et al (1985) Retrospective Not reported Yes No 33 11/18 (61) 9/15 (60)
Ziegler et al (1991) Prospective Not reported Yes No Autopsy 37 10/24 (42) 9/13 (69)
Botet et al (1991) Prospective Not reported Yes No 42 23/29 (79) 8/13 (62)
Sondenaa et al (1992) Retrospective Not reported Yes No 42 5/23 (22) 18/19 (95)
Yoshikane et al (1994) Not reported Yes Yes No 25 4/12 (33) 11/13 (85)
Greenberg et al (1994) Prospective Not reported Yes No 16 5/10 (50) 4/6 (67)
Flanagan et al (1997) Retrospective Yes Yes No 29 5/18 (28) 8/11 (73)
Nishimaki et al (1999) Prospective Not reported Yes No 210 81/136 (60) 55/74 (74)
Choi et al (2000) Prospective Yes Yes No 48 13/32 (41) 16/16 (100)
Wren et al (2002) Retrospective Not reported Yes Yes Autopsy/follow-up 21 4/7 (57) 10/14 (71)
Vazquez-Sequeiros et al (2003) Prospective Yes Yes Yes 124 40/85 (47) 36/39 (92)
Wu et al (2003) Not reported No Yes No 41 17/22 (77) 15/19 (79)
Yoon et al (2003) Prospective Yes Yes No Follow-up 81 12/39 (31) 36/42 (86)
Rasanen et al (2003) Prospective Not reported Yes No Follow-up 32 9/19 (47) 12/13 (92)
Heeren et al (2004) Not reported Yes Yes Yes Follow-up 60 17/39 (44) 19/21 (90)
Sihvo et al (2004) Prospective No Yes No 43 11/26 (42) 14/17 (82)
Lowe et al (2005) Prospective Yes Yes Yes 59 37/44 (84) 10/15 (67)
Abdominal lymph node metastases
Quint et al (1985) Retrospective Not reported Yes No 33 2/3 (67) 26/30 (87)
Becker et al (1986) Retrospective Yes Yes No 50 13/23 (57) 27/27 (100)
Watt et al (1989) Prospective Yes Yes No 65 11/35 (31) 26/30 (87)
Van Overhagen et al (1993) Prospective Yes Yes Yes 86 13/27 (48) 55/59 (93)
Parmar et al (2002) Retrospective Not reported Yes Yes 20 5/18 (28) 1/2 (50)
Distant metastases
Van Overhagen et al (1993) Prospective Yes Yes Yes 113 38/54 (70) 50/59 (85)
Flamen et al (2000) Prospective Yes Yes No Follow-up 74 14/34 (41) 33/40 (83)
Wren et al (2002) Retrospective Not reported Yes Yes Autopsy/follow-up 24 10/12 (83) 9/12 (75)
Rasanen et al (2003 Prospective Not reported Yes No Follow-up 42 5/15 (33) 26/27 (96)
Yoon et al (2003) Prospective Yes Yes No Follow-up 81 1/7 (14) 70/74 (95)
Sihvo et al (2004) Prospective No Yes No 55 6/19 (32) 35/36 (97)
Lowe et al (2005) Prospective Yes Yes Yes 48 21/26 (81) 18/22 (82)
TP¼true-positive; FN¼false-negative; FP¼false-positive; TN¼true-negative; CT¼computed tomography; FNA¼fine-needle aspiration.
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Clinical StudiesTable 3 Characteristics of studies containing absolute numbers of TP, FN, FP, and TN test results of FDG-PET for regional lymph node metastases and distant metastases
Study Study type
Blinded
interpretation
of test results
Resection as
reference
standard
FNA as
reference
standard
Other reference
standard
Number of
patients Sensitivity (%) Specificity (%)
Regional lymph node metastases
Luketich et al (1997) Retrospective Not reported No Yes Follow-up 21 9/20 (45) 1/1 (100)
Flanagan et al (1997) Retrospective Yes Yes No 29 13/18 (72) 9/11 (82)
Lerut et al (2000) Prospective Not reported Yes Yes 29 4/18 (22) 10/11 (91)
Choi et al (2000) Prospective Yes Yes No 48 26/32 (81) 14/16 (88)
Wren et al (2002) Retrospective Not reported Yes Yes Autopsy/follow-up 21 5/7 (71) 12/14 (86)
Yoon et al (2003) Prospective Yes Yes No Follow-up 81 25/39 (64) 29/42 (69)
Rasanen et al (2003) Prospective Not reported Yes No Follow-up 32 7/19 (37) 13/13 (100)
Heeren et al (2004) Not reported Yes Yes Yes Follow-up 61 22/40 (55) 15/21 (71)
Sihvo et al (2004) Prospective No Yes No 43 9/26 (35) 17/17 (100)
Lowe et al (2005) Prospective Yes Yes Yes 59 36/44 (82) 9/15 (60)
Distant metastases
Luketich et al (1997) Retrospective Not reported No Yes Follow-up 35 7/8 (88) 25/27 (93)
Lerut et al (2000) Prospective Not reported Yes Yes 42 10/13 (77) 26/29 (90)
Flamen et al (2000) Prospective Yes Yes No Follow-up 74 25/34 (74) 36/40 (90)
Wren et al (2002) Retrospective Not reported Yes Yes Autopsy/follow-up 24 8/12 (67) 11/12 (92)
Yoon et al (2003) Prospective Yes Yes No Follow-up 81 3/7 (43) 73/74 (99)
Rasanen et al (2003) Prospective Not reported Yes No Follow-up 42 7/15 (47) 24/27 (89)
Sihvo et al (2004) Prospective No Yes No 55 10/19 (53) 32/36 (89)
Heeren et al (2004) Not reported Yes Yes Yes Follow-up 74 21/27 (78) 43/47 (91)
Lowe et al (2005) Prospective Yes Yes Yes 48 21/26 (81) 20/22 (91)
TP¼true-positive; FN¼false-negative; FP¼false-positive; TN¼true-negative; FDG¼
18F-fluoro-2-deoxy-D-glucose positron emission tomography; FNA¼fine-needle aspiration.
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showever, was similar. Furthermore, we found that the diagnostic
performance of FDG-PET was significantly higher than that of CT
for distant metastases.
Based on these results, EUS was shown to be particularly useful
for the exclusion of regional lymph node metastases. The low
number of false-negative results for EUS meant that a negative EUS
result will be in most patients a truly negative one. The sensitivities
of CT and FDG-PET for the detection of regional lymph node
metastases were lower. It is already known that lymph nodes
adjacent to the primary oesophageal cancer are difficult to
discriminate from the primary tumour with FDG-PET (McAteer
et al, 1999), which is due to the intense activity in the primary
cancer (Flanagan et al, 1997) and the limited spatial resolution of
PET (Luketich et al, 1997; Rankin et al, 1998). Low sensitivity of
CT for regional lymph node can at least partly be explained by the
fact that CT is not able to detect metastases in normal-sized lymph
nodes (Choi et al, 2000).
Computed tomography and/or FDG-PET can be used to confirm
that an enlarged regional lymph node is indeed metastatic, as the
number of false-positive results was found to be relatively low for
both investigations. However, a better option nowadays is to
perform EUS-guided FNA to confirm metastatic disease. This is in
line with recommendations in the literature, in which EUS-FNA,
CT, and/or FDG-PET are advocated for the exclusion of the
presence of regional lymph node metastases in oesophageal cancer
patients, particularly if this will affect a treatment decision in these
patients. In several studies, it has been demonstrated that the
results of EUS-FNA were better than those of EUS alone for
determining N stage (Eloubeidi et al, 2001; Vazquez-Sequeiros
Table 4 Summary of the number of included studies, the total number of patients, pooled sensitivity, pooled specificity, and the pooled log odds ratio
given per disease and investigation
Disease Investigation
Number of included
studies
Total number of
patients
Pooled sensitivity
(95% CI)
Pooled specificity
(95% CI)
Pooled log odds ratio
(95% CI)
Regional lymph node
metastases
EUS 31 1841 0.80 (0.75–0.84) 0.70 (0.65–0.75 1.94 (1.71–2.17)
Regional lymph node
metastases
CT 17 943 0.50 (0.41–0.60) 0.83 (0.77–0.89) 1.40 (1.08–1.72)
Regional lymph node
metastases
FDG-PET 10 424 0.57 (0.43–0.70) 0.85 (0.76–0.95) 1.71 (1.22–2.20)
Celiac lymph node
metastases
EUS 5 339 0.85 (0.72–0.99) 0.96 (0.92–1.00) 3.89 (2.67–5.11)
Abdominal lymph node
metastases
CT 5 254 0.42 (0.29–0.54) 0.93 (0.86–1.00) 1.74 (0.45–3.04)
Distant metastases CT 7 437 0.52 (0.33–0.71) 0.91 (0.86–0.96) 2.10 (1.59–2.62)
Distant metastases FDG-PET 9 475 0.71 (0.62–0.79) 0.93 (0.89–0.97) 2.93 (2.41–3.45)
CI¼confidence interval; EUS¼endoscopic ultrasonography; CT¼computed tomography; FDG¼
18F-fluoro-2-deoxy-D-glucose positron emission tomography.
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Figure 1 Funnel plot in which the number of patients included in studies
on the use of EUS for the detection of regional lymph node metastases was
plotted against the log of the diagnostic odds ratio (D).
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Figure 2 Funnel plot in which the number of patients included in studies
on the use of CT for the detection of regional lymph node metastases was
plotted against the log of the diagnostic odds ratio (D).
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Figure 3 Summary receiver operating characteristic curves for EUS,
FDG-PET, and CT for detection of regional lymph node metastases.
P¼not significant.
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set al, 2001; Parmar et al, 2002; van Vliet et al, 2006), because EUS
combined with FNA allowed a cytological differentiation between
reactive (non-malignant) and malignant lymph nodes (van Vliet
et al, 2006).
The presence or absence of regional lymph node metastases has
little direct consequences for the treatment decision. For example,
patients with a T1–3 tumour without distant metastases and who
are fit enough will receive a resection, which is mostly irrespective
of the presence of regional lymph node metastases. Nonetheless,
it is important to know whether regional lymph node metastases
are present if an endoscopic treatment option is considered in
patients with early-stage oesophageal cancer. In addition, the
presence of regional lymph node metastases plays a role in the
comparison of treatment modalities of oesophageal cancer, for
example if comparing neoadjuvant therapy plus surgery vs surgery
alone, and has consequences for the prognosis of patients.
Therefore, we think that it is important to analyse whether
detected lymph nodes are indeed metastatic (by using FNA),
particularly if this will affect a treatment decision in patients.
It is also of clinical relevance to determine whether celiac and/or
other abdominal lymph node metastases are present. If present,
these are considered to be distant metastases (M1b), depending on
the localisation of the primary tumour, which could change a
treatment decision from a curative to a palliative option. As several
articles on CT for staging oesophageal cancer reported not only on
celiac lymph nodes, but also on other abdominal lymph nodes, the
pooled results of EUS for the detection of celiac lymph node
metastases and the pooled results of CT for the detection of
abdominal lymph node metastases could not be fairly compared.
Nevertheless, as the results of EUS and CT were clearly different,
with EUS results being obviously better, it seems likely that EUS is
the preferred investigation to determine whether or not celiac
lymph node metastases are present in patients with oesophageal
cancer. It is important to realise, however, that not all abdominal
lymph nodes can be determined with EUS, as the EUS probe has a
limited penetration depth of approximately 5 cm. Although no
data are available in the literature, we recommend combining EUS
with CT to investigate whether, apart from celiac lymph node
metastases, other abdominal lymph node metastases are present.
The staging results of EUS for celiac lymph node metastases
were even better than those for regional lymph node metastases.
An explanation for this could be that only a few studies have
reported on the use of EUS for the detection of malignant celiac
lymph nodes, which were likely performed in high-volume EUS
centres. In contrast, studies that reported EUS results for regional
lymph node metastases were performed not only in high-volume
centres, but also in low-volume centres. We recently reported that
the results of EUS performed in a centre where o50 EUS
procedures per endoscopist per year (low-volume centres) are
performed were inferior to those from high-volume EUS centres
(450 EUS procedures per endoscopist per year) (van Vliet et al,
2006).
Both CT and FDG-PET can be used to detect distant metastases,
which determines whether a patient is suitable for a curative
treatment option. The reported results of the investigations varied
widely (Tables 2 and 3) and it is currently difficult to determine
how these investigations should be used during staging of patients
with oesophageal cancer. The pooled sensitivity of CT for the
detection of distant metastases was lower than that of FDG-PET,
whereas specificity was equivalent. The results for FDG-PET were
comparable to the results found in a previous meta-analysis on
FDG-PET for this indication (van Westreenen et al, 2004). In our
SROC analysis, we found that the diagnostic performance of FDG-
PET was significantly better than that of CT (Figure 4). This
method takes both sensitivity and specificity into account and
adjusts for potential differences in test thresholds across studies.
Two studies in which FDG-PET was directly compared with CT for
the detection of distant metastases (Luketich et al, 1999; Flamen
et al, 2000) demonstrated that both sensitivity and specificity of
FDG-PET for distant metastases were higher compared to those of
CT. In contrast, other studies comparing FDG-PET with CT found
similar accuracies for both investigations for the detection of
distant metastases (Wren et al, 2002; Kneist et al, 2003, 2004;
Rasanen et al, 2003; Sihvo et al, 2004).
Several publications have reported on the additional value of
FDG-PET for the detection of distant metastases, and it has been
demonstrated that distant metastases were detected with FDG-PET
in 0–20% of patients with oesophageal cancer, which were not
found with other investigations. In patients in whom distant
metastases were detected with FDG-PET, the treatment plan was
corrected from a curative to a palliative option and unnecessary
surgery was precluded (Block et al, 1997; Flanagan et al, 1997; Kole
et al, 1998; Rankin et al, 1998; Luketich et al, 1999; Flamen et al,
2000; Lerut et al, 2000; Wren et al, 2002; Imdahl et al, 2004; van
Westreenen et al, 2005). Disadvantages of FDG-PET include the
high costs and the fact that it mostly needs to be combined with CT
to localise a lesion that is visualised by FDG-PET. It remains to be
established whether the costs of FDG-PET are compensated for by
the cost reduction of resections that are prevented due to the
finding of additional metastases with FDG-PET. In the early days
of FDG-PET, it was unclear whether FDG-PET should be the initial
investigation to detect metastases in oesophageal cancer, or,
alternatively, whether FDG-PET should be performed if EUS and
CT have already been performed. The performance of FDG-PET
alone does not seem to be the ideal method for the detection of
distant metastases, but the combined use of FDG-PET and CT
could well be of significance. This is already on the horizon, as
integrated FDG-PET/CT machines are increasingly becoming
available. Unfortunately, the value of PET-CT could not be clearly
determined by our meta-analysis, as there were not enough well-
performed studies available.
Our meta-analysis has some limitations. First, abstracts were
assessed to identify articles reporting on the results of EUS, CT,
and FDG-PET. There is a small risk that some articles of which the
abstract revealed that it was highly unlikely that the article
contained information on the results of EUS, CT, and/or FDG-PET
were excluded from evaluation. It is also possible that articles with
results on EUS, CT, and FDG-PET did not match the search terms.
To correct for this, references of included articles and reviews were
examined for additional articles that met the inclusion criteria.
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Figure 4 Summary receiver operating characteristic curves for FDG-PET
and CT for detection of distant metastases. Po0.03.
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sSecond, only studies with the results of EUS, CT, and/or FDG-
PET for the detection of lymph node or distant metastases from
which absolute numbers of TP, FN, FP, and TN test results were
available or derivable were included, which is advocated in the
STARD guidelines (Bossuyt et al, 2003). Several studies did not
report these absolute numbers precluding thorough statistical
evaluation. In addition, some of our analyses were based on
limited numbers of publications and it could therefore be that
some differences in this meta-analysis were not statistically
significant due to these limited sample sizes.
Third, it seems likely that verification bias played a role in all
articles included in our meta-analysis, because the results of
staging investigations performed in patients with oesophageal
cancer were used to decide whether or not FNA should be
performed and whether or not patients could undergo a resection.
Funnel plots, as shown in Figures 1 and 2, revealed that publication
bias was probably not present in the meta-analysis regarding EUS
and CT for the detection of regional lymph node metastases.
Nevertheless, for the other analyses, the number of included
studies was too small to evaluate publication bias.
Fourth, the time period in which the evaluated articles were
published might also be a factor to consider. The initial reported
results of a new investigation are often more favorable than those
published later in time if the procedure is used in a less selected
study population. We accounted for this potential effect by
including the year of publication as a covariate in our analysis.
The results showed that the publication year was not a significant
predictor of diagnostic performance in our study.
Fifth, the methodological quality of some studies included in
this meta-analysis was limited. For example, several studies that
are shown in Tables 1–3 were retrospectively performed and in
some studies the test results were not blindly interpreted. In
addition, missing values were present for some covariates,
particularly for the covariates inclusion (consecutive or not) and
interpretation (blinded or not).
Sixth, only a few articles on CT and EUS reported nodal cutoff
sizes for positivity. For this reason, we could not perform a sub-
analysis to determine which nodal cutoff size was most accurate. In
addition, only a few articles reported on the location of the tumour
and, therefore, it was not possible to determine whether the results
of EUS differed for the various locations of the tumours, that is,
cervical, upper 1/3 thoracic, central 1/3 thoracic, lower 1/3
thoracic, and gastrooesophageal junction. In addition, it would
have been clinically interesting if the localisation of the primary
tumour could have been combined with nodal status. The same
was true for the location of distant metastases, which was also not
reported in the majority of studies and, if reported, results were
not given per location. Therefore, it was not possible to calculate
results for the different metastatic locations in our meta-analysis.
Finally, it is known that experience is an important factor in
performing EUS. Nevertheless, in the majority of articles, it was
not reported how experienced endoscopists were and, therefore,
we could not determine whether EUS results varied for different
levels of experience. Moreover, no information was given on the
number of patients with squamous cell carcinoma or adenocarci-
noma in several studies and, if reported, results were mostly not
reported per tumour histology.
In conclusion, the presence of malignant regional lymph nodes
can be determined with EUS, CT, and FDG-PET. Of these, EUS has
the highest sensitivity but also the lowest specificity for regional
lymph node metastases. To exclude the presence of regional lymph
node metastases, EUS should be used, whereas detected lesions
should be confirmed with FNA, or, alternatively, with CT and/or
FDG-PET, particularly if this will affect a treatment decision in
patients. Both EUS and CT should probably be performed to
determine whether abdominal lymph node metastases are present,
with EUS being highly sensitive for celiac lymph node metastases
and CT being performed to detect other abdominal lymph node
metastases. Both CT and FDG-PET can be used to detect the
presence of distant metastases; however, the results suggest that
FDG-PET has a higher diagnostic performance than CT. Nonetheless,
it seems likely that its combined use could be of clinical value, with
FDG-PET detecting possible metastases and CT confirming or
excluding their presence and precisely determining the location(s).
Nowadays, integrated FDG-PET/CT machines are increasingly being
available and their use has become more common.
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